Eli Lilly and Novo Nordisk Shares Plunge Amid Ozempic Vision Loss Fears
Novo Nordisk shares dropped nearly 4%, and Eli Lilly saw a more than 1% decline after ...
Read moreNovo Nordisk shares dropped nearly 4%, and Eli Lilly saw a more than 1% decline after ...
Read moreEli Lilly’s new Alzheimer's drug, donanemab, received unanimous backing from FDA advisers on June 10, 2024.
Read more© 2024 Lumida Wealth Management LLC is an SEC registered investment adviser. Disclaimer.
© 2024 Lumida Wealth Management LLC is an SEC registered investment adviser. Disclaimer.